Spectra is thus unique in its ability to disentangle tumor reactivity and exhaustion programs in CD8+ T cells, making it possible to identify tumor-reactive populations across cancer types and find novel mediators of tumor reactivity that can be associated with patient-level therapeutic responses and nominated as candidate targets for enhancing ICT efficacy. This evidence concerns the gene CD8A and neoplasm.